MacroGenics, Inc. (MGNX) SVP Jon Marc Wigginton Sells 5,000 Shares
MacroGenics, Inc. (NASDAQ:MGNX) SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $20.00, for a total transaction of $100,000.00. Following the completion of the transaction, the senior vice president now directly owns 35,000 shares of the company’s stock, valued at $700,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
Jon Marc Wigginton also recently made the following trade(s):
- On Wednesday, October 25th, Jon Marc Wigginton sold 10,000 shares of MacroGenics stock. The shares were sold at an average price of $20.00, for a total transaction of $200,000.00.
MacroGenics, Inc. (MGNX) traded up $0.33 during mid-day trading on Wednesday, reaching $20.03. 213,800 shares of the company’s stock were exchanged, compared to its average volume of 261,368. MacroGenics, Inc. has a 1 year low of $14.36 and a 1 year high of $28.90.
MacroGenics (NASDAQ:MGNX) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($1.28) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.09) by ($0.19). MacroGenics had a negative return on equity of 69.31% and a negative net margin of 1,526.55%. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $5.50 million. During the same period last year, the firm earned ($0.97) earnings per share. The company’s revenue for the quarter was down 48.5% compared to the same quarter last year. equities analysts predict that MacroGenics, Inc. will post -0.7 EPS for the current year.
Hedge funds have recently added to or reduced their stakes in the business. Russell Investments Group Ltd. bought a new position in MacroGenics during the second quarter worth $133,000. Legal & General Group Plc boosted its position in MacroGenics by 4.3% during the second quarter. Legal & General Group Plc now owns 7,925 shares of the biopharmaceutical company’s stock worth $138,000 after purchasing an additional 328 shares during the period. SG Americas Securities LLC boosted its position in MacroGenics by 92.2% during the second quarter. SG Americas Securities LLC now owns 10,812 shares of the biopharmaceutical company’s stock worth $189,000 after purchasing an additional 5,187 shares during the period. Parametric Portfolio Associates LLC bought a new position in MacroGenics during the second quarter worth $203,000. Finally, Virtu KCG Holdings LLC bought a new position in MacroGenics during the second quarter worth $232,000. 82.75% of the stock is owned by hedge funds and other institutional investors.
Several equities analysts recently weighed in on MGNX shares. Stifel Nicolaus reissued a “buy” rating and issued a $34.00 target price on shares of MacroGenics in a research note on Tuesday, September 12th. Zacks Investment Research cut shares of MacroGenics from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Cowen and Company reissued a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $26.00 target price on shares of MacroGenics in a research note on Friday, September 1st. Finally, ValuEngine raised shares of MacroGenics from a “strong sell” rating to a “sell” rating in a research note on Friday, September 1st. Two research analysts have rated the stock with a sell rating, three have issued a hold rating and nine have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $30.10.
MacroGenics Company Profile
MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.
Receive News & Ratings for MacroGenics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.